Navigation Links
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Date:7/21/2008

September meeting to focus on use of Zevalin as consolidation therapy after

remission induction in previously untreated patients with follicular

lymphoma

SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The basis for the filing would be data from the First-line Indolent Trial that CTI recently gained access to through an agreement with Bayer Schering Pharma.

"We are pleased to have scheduled a meeting with the FDA to discuss a label expansion for Zevalin which could broaden its availability to patients," said James A. Bianco, M.D., President and CEO of Cell Therapeutics. "We continue to make progress with Zevalin on multiple fronts with clarity on reimbursement rates, deployment of our national sales team and now the opportunity to meet with the FDA to discuss possibly expanding the label for Zevalin."

About the Phase III First-line Indolent (FIT) Trial

The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete response after receiving standard first-line chemotherapy regimens. The FIT trial results were presented in one oral and two poster presentations at the American Society of Hematology (ASH) conference in December 2007. The FIT trial demonstrated that when used as a first-line consolidation therapy for patients with follicular non-Hodgkin's lymphoma, Zevalin significantly impro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
5. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
6. APIC Conference to Discuss MRSA Elimination
7. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
8. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
9. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
Breaking Medicine News(10 mins):Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... four randomized controlled trials that directly compared two different ... radiofrequency ablation (RFA) significantly improves patient survival compared to ... findings are in the February issue of Hepatology ... on behalf of the American Association for the Study ...
... women who should receive radiation after a mastectomy are ... new study from researchers at the University of ... women who were treated with a mastectomy for breast ... who fell clearly within guidelines recommending radiation treatment after ...
... one million families by offering an economic opportunity in ... Corporation Chairman and CEO Roger Barnett will launch a ... support to one million families in 2009. The ... "Families are struggling to make ends meet in ...
... WASHINGTON, Feb. 3 Green tea products have become ... shown evidence of its benefit against a variety of ... some components of green tea may counteract the anticancer ... be contraindicated for patients taking this medicine to ensure ...
... Feb. 3 America,s oldest voluntary health organization is ... Nolan. Elected National Board Chair, after more than a ... has successfully steered the American Lung Association to tackle ... emphasis of his chairmanship has been to build on ...
... to increased mortality, , , TUESDAY, Feb. 3 (HealthDay News) -- ... needs to be taken seriously, a new study concludes. , ... goes up for at least five years following any low-trauma ... fracture. , "All low-trauma fractures are associated with premature mortality, ...
Cached Medicine News:Health News:Radiofrequency treatment better than ethanol injection for small liver tumors 2Health News:U-M Study: 19% of Breast Cancer Patients Don't Receive Recommended Radiation After Mastectomy 2Health News:Shaklee Hits the Road With Its Infinite Possibilities Tour 2Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 2Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 3Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 4Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Fractures in Older Adults Up Death Risk 2
... prisms are of superior quality. Set of 16 includes 1/2, ... 35, 40, 45, and 50 diopter plus Red Lens. Each ... lbs)., , 4445xx , ,These prisms are of superior quality. ... 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, ...
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
... PC is the most powerful Isolated ESU on ... It is the only ESU that allows the ... field with a standard ES pencil. Excalibur Plus ... minimum necessary voltage for smooth cutting through various ...
Diamond phaco knife keratome shaped blade straight. 3.2 mm wide....
Medicine Products: